Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 26, 2023; 11(27): 6558-6564
Published online Sep 26, 2023. doi: 10.12998/wjcc.v11.i27.6558
Triplet regimen as a novel modality for advanced unresectable hepatocellular carcinoma: A case report and review of literature
Ying Zhao, Guo-Sheng He, Gong Li
Ying Zhao, Guo-Sheng He, Gong Li, Department of Radiation Oncology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China
Author contributions: Zhao Y analyzed the data and wrote the manuscript; He GS collected the data; Li G edited and approved the manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gong Li, MD, Doctor, Researcher, Department of Radiation Oncology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, No. 168 Litang Road, Changping District, Beijing 102218, China. dr_gongli@163.com
Received: June 6, 2023
Peer-review started: June 6, 2023
First decision: August 8, 2023
Revised: August 22, 2023
Accepted: August 31, 2023
Article in press: August 31, 2023
Published online: September 26, 2023
Processing time: 106 Days and 4.6 Hours
Core Tip

Core Tip: Primary hepatoma patients with inferior vena cava tumor thrombus and portal vein tumor thrombus are rare, and both are inferior prognostic factors for such patients. There are no worldwide consensuses or guidelines on the diagnosis and treatment of hepatocellular carcinoma patients with macrovascular invasion. We used a new treatment model for this patient: radiotherapy combined with target therapy followed by immune maintenance therapy; and achieved extended survival.